A retrospective clinical study that is supposed to finish in late 2025 “Clinical and Biochemical Features for the Identification of Dominant Calpainopathies (DOM-CAL)” (https://clinicaltrials.gov/study/NCT05956132) should expand the number of known variants associated with autosomal dominant calpainopathy and hopefully lead to more research to understand some of the poorly understood facets of calpain-3 function. Here, CAPN3 is linked to autosomal recessive limb-girdle muscular dystrophy type 2A.